ES2192200T3 - Intercambiador de especificidad de antigenos/anticuerpos. - Google Patents

Intercambiador de especificidad de antigenos/anticuerpos.

Info

Publication number
ES2192200T3
ES2192200T3 ES95918240T ES95918240T ES2192200T3 ES 2192200 T3 ES2192200 T3 ES 2192200T3 ES 95918240 T ES95918240 T ES 95918240T ES 95918240 T ES95918240 T ES 95918240T ES 2192200 T3 ES2192200 T3 ES 2192200T3
Authority
ES
Spain
Prior art keywords
antigen
antibody
exchanger
specificity
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918240T
Other languages
English (en)
Inventor
Matti Sallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tripep AB
Original Assignee
Tripep AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep AB filed Critical Tripep AB
Application granted granted Critical
Publication of ES2192200T3 publication Critical patent/ES2192200T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBE UN INTERCAMBIADOR CON ESPECIFICIDAD PARA ANTIGENO/ANTICUERPO. COMPRENDE: A) UNA SECUENCIA AMINOACIDA CORRESPONDIENTE A LA SECUENCIA AMINOACIDA DE UN ANTICUERPO QUE SE UNE SELECTIVAMENTE A UN DETERMINADO ANTIGENO, QUE INCLUYE UN HAPTENO, B) UNIDA MEDIANTE UN ENLACE A C) UNA SECUENCIA AMINOACIDA, A LA CUAL SE UNE UN ANTICUERPO DETERMINADO. ASIMISMO, SE DESCRIBE UN REACTIVO DE DIAGNOSTICO QUE COMPRENDE UN INTERCAMBIADOR CON ESPECIFICIDAD PARA ANTIGENO/ANTICUERPO, DE ACUERDO CON LA INVENCION. DICHO REACTIVO DE DIAGNOSTICO, PUEDE SER UTILIZADO P.EJ., EN LUGAR DE ANTISUEROS O ANTICUERPOS MONOCLONALES, EN SISTEMAS DE ENSAYO IN VITRO, COMO ENSAYOS INMUNOLOGICOS. ADEMAS, SE DESCRIBE UN METODO DE TRATAMIENTO DE UNA ENFERMEDAD O ALTERACION, CAUSADA POR UN ANTIGENO CONOCIDO EN UN INDIVIDUO, QUE PRECISA UN MAYOR NUMERO DE ANTICUERPOS ESPECIFICOS PARA DICHO ANTIGENO. EN EL METODO SE CONSIGUE UN INTERCAMBIADOR CON ESPECIFICIDAD ANTIGENO/ANTICUERPO HECHO A MEDIDA. DICHO METODO SE PUEDE USAR P.EJ., PARA REDIRIGIR LOS ANTICUERPOS CONTRA POLIOVIRUS DEL PACIENTE, PARA LUCHAR CONTRA LA INFECCION POR HIV EN DICHO PACIENTE.
ES95918240T 1994-04-28 1995-04-27 Intercambiador de especificidad de antigenos/anticuerpos. Expired - Lifetime ES2192200T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401460A SE9401460D0 (sv) 1994-04-28 1994-04-28 Antigen/antibody specificity exhanger

Publications (1)

Publication Number Publication Date
ES2192200T3 true ES2192200T3 (es) 2003-10-01

Family

ID=20393822

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918240T Expired - Lifetime ES2192200T3 (es) 1994-04-28 1995-04-27 Intercambiador de especificidad de antigenos/anticuerpos.

Country Status (7)

Country Link
US (1) US5869232A (es)
EP (1) EP0759037B1 (es)
AU (1) AU2423295A (es)
DE (1) DE69530078T2 (es)
ES (1) ES2192200T3 (es)
SE (1) SE9401460D0 (es)
WO (1) WO1995029938A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660842B1 (en) * 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6417324B1 (en) * 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7053177B1 (en) 1997-05-15 2006-05-30 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
JP4129298B2 (ja) * 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
US7135457B1 (en) 1997-05-15 2006-11-14 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
JP4004230B2 (ja) * 1998-11-06 2007-11-07 株式会社三菱化学ヤトロン 架橋アビジン含有新規複合体、架橋アビジンを用いる分析方法、並びに分析用試薬及びキット
US6800296B1 (en) * 1999-05-19 2004-10-05 Massachusetts Institute Of Technology Modification of surfaces using biological recognition events
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
KR20030034194A (ko) * 2000-09-19 2003-05-01 트리펩 아베 병원체 내에서 수용체에 대한 항체를 재유도하는리간드/수용체 특이성 교환기
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP2230249A3 (en) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US20090092631A1 (en) * 2007-03-26 2009-04-09 Tripep Ab Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response
CN102459298A (zh) 2009-05-05 2012-05-16 阿尔特姆恩科技责任有限公司 化学可编程免疫
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8428487D0 (en) * 1984-11-12 1984-12-19 Ils Ltd Immunoassays
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5260189A (en) * 1988-12-20 1993-11-09 Immunodiagnostics, Inc. Synthetic HIV-like peptides their compositions and uses
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
DE69309472T2 (de) * 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
GB9412166D0 (en) * 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies

Also Published As

Publication number Publication date
DE69530078T2 (de) 2004-02-26
AU2423295A (en) 1995-11-29
DE69530078D1 (de) 2003-04-30
WO1995029938A1 (en) 1995-11-09
EP0759037A1 (en) 1997-02-26
EP0759037B1 (en) 2003-03-26
SE9401460D0 (sv) 1994-04-28
US5869232A (en) 1999-02-09

Similar Documents

Publication Publication Date Title
ES2192200T3 (es) Intercambiador de especificidad de antigenos/anticuerpos.
Potter et al. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants
ES2016426A6 (es) Un procedimiento para detectar la presencia de anticuerpos frente a virus del sida en el suero humano.
DK609985A (da) Adhesin-antigener, antistoffer mod disse og dna-fragmenter, som indkoder antigenerne
ES2194782T3 (es) Procedimiento mejorado de deteccion de bacterias acidorresistentes del genero helicobacter en las heces.
Yohannes et al. Comparative evaluation of the Rose Bengal plate test, standard tube agglutination test and complement fixation test for the diagnosis of human brucellosis
Ownby et al. Loss of volunteer blood donors because of unconfirmed enzyme immunoassay screening results. Retrovirus Epidemiology Donor Study
Portanti et al. Development and evaluation of diagnostic tests for the serological diagnosis of brucellosis in swine
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
WO2003068820A9 (fr) IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
ES2044976T3 (es) Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.
Davidsohn et al. Immunohematological studies in hemolytic anemia
ES2100164T3 (es) Deteccion y tratamiento de infecciones con inmunoconjugado.
Chantler et al. Evaluation of the immunological specificity of fluorescein-labelled anti-human IgM conjugates
Sepetjian et al. Investigation of a specific IgM antibody test in neonatal congenital syphilis
Akiso et al. Vaginal microbiome dysbiosis and sexually transmitted infections correlate with concentrations of immunoglobulin isotypes in human cervicovaginal mucus: insights into HIV-1 transmission
Judelsohn et al. Rubella in Bermuda: Termination of an epidemic by mass vaccination
Pande et al. A case report of Plasmodium vivax, Plasmodium falciparum and dengue co-infection in a 6 months pregnancy
Sprino et al. Intestinal immune response of feeder pigs to infection with transmissible gastroenteritis virus
ES2056780T1 (es) Un procedimiento para el aislamiento de virus de hav.
TANAKA The agar-diffusion technique in studies of immunity to adenoviruses
Ogunremi et al. Validation of the indirect fluorescent antibody and the complement fixation tests for the diagnosis of Theileria equi
DK1028127T3 (da) Antistoffer og diagnostiske metoder til diagnose af Pestivira
Peetermans et al. Tropical sprue after travel to Tanzania
Leder Simple paper electrophoretic method for detecting macroglobulinaemia